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Lipomas have often been associated with mtDNA mutations and were mainly observed
in patients with mutation in mitochondrial tRNAlysine which is also the most frequent
mutation associated with MERRF. Up to date, no systematic studies have been
developed in order to assess the incidence of lipomas in large cohorts of mitochondrial
patients.The aim of this study is to analyze the incidence and characteristics of lipomas
among an Italian cohort of patients with mitochondrial diseases. A retrospective,
database-based study (Nation-wide Italian Collaborative Network of Mitochondrial
Diseases) of patients with lipomas was performed. A total of 22 (1.7%) patients with
lipomas have been identified among the 1,300 mitochondrial patients, enrolled in the
Italian database. In about 18% multiple systemic lipomatosis (MSL) was the only clinical
manifestation; 54% of patients showed a classical MERRF syndrome. Myopathy, alone
or in association with other symptoms, was found in 27% of patients. Lactate was
elevated in all the 12 patients in which was measured. Muscle biopsy was available
in 18/22 patients: in all of them mitochondrial abnormalities were present. Eighty six
percent had mutations in mtDNA coding for tRNA lysine. In most of patients, lipomas
were localized along the cervical-cranial-thoracic region. In 68% of the patients were
distributed symmetrically. Only two patients had lipomas in a single anatomical site (1 in
right arm and 1 in gluteus maximum). MSL is often overlooked by clinicians in patients
with mitochondrial diseases where the clinical picture could be dominated by a severe
multi-systemic involvement. Our data confirmed that MSL is a rare sign of mitochondrial
disease with a strong association between multiple lipomas and lysine tRNA mutations.
MSL could be considered, even if rare, a red flag for mitochondrial disorders, even in
patients with an apparently isolated MSL.
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INTRODUCTION
Multiple systemic lipomatosis (MSL) is a rare disorder involving
adipose tissue and characterized, clinically, by the development
of non-encapsulated lipomas usually distributed in the cervical–
cranial–thoracic region (1–3). Since the first description, MSL
was differently named referring to scientists who described some
peculiar clinical features of the disease as Brodie syndrome or
Madelung‘s disease or Launois–Bensaude disease (1–3).
Lipomatous masses often occur in the third/fourth decade
of life. MSL is largely prevalent among males and it has been
correlated with high alcohol intake (4, 5). Lipomas ‘distribution
is prevalent along the midline, sparing distal portion of the
limbs. Visceral sites can also be involved. The course of MSL
is usually benign although some authors reported a higher
mortality comparing with the general population. Respiratory
airways obstruction by cervical lipomatous masses is a common
serious complication (4, 6).
The pathogenesis of lipoma formation is unclear but
sporadic observations have linked MSL with mitochondrial
dysfunction (7).
In about 28% of MSL patients, mitochondrial alterations (e.g.,
ragged red fibers –RRF- and COX negative fibers) were noted in
muscle biopsies (8). Mitochondrial DNA mutations have been
recurrently diagnosed in MSL patients (about 16% of tested
patients) being the mitochondrial lysine tRNA (m. 8344 A>G,
known to be associated with Myoclonic-Epilepsy with Ragged
Red Fibers –MERRF- syndrome) (9–12). In addition recently,
MSL has been observed in a family with multiple deletion of
mitochondrial DNA and a mutation in Mitofusin 2 (13).
The pathogenesis of lipomas in MSL seems to be due to
alteration of brown fat tissue growth regulation, this hypothesis
is supported by the typical anatomic distribution of the masses
and from results of morphological studies. Lipomatous masses
are indeed located along the midline of the body, following the
distribution of brown adipose tissue (BAT) present in newborns
(14). BAT, contrary to the white adipose tissue, produces heat
because of an overexpression of UCP1 (Uncoupling Protein
1) that is responsible for the uncoupling of the oxidative
phosphorylation from ATP production (15). MSL tissues show
overexpression of UCP1, confirming the it may be originated
from BAT (16).
While mitochondrial function in patients with idiopathicMSL
has been systematically studied (9), the prevalence of MSL in
mitochondrial patients has been only evaluated in few cases
reports. Our study aims to explore the presence of this syndrome
in a large cohort of Italian patients with mitochondrial diseases.
MATERIALS AND METHODS
We reviewed data of 1,300 patients reported in the database of
the Nation-wide Italian Collaborative Network of Mitochondrial
Diseases searching for the presence of lipomatosis as clinical
feature. Aggregated data were using to evaluate: (1) incidence of
lipomas among the population of Italian mitochondrial patients,
(2) molecular defects present in patients with MSL, (3) clinical
characteristics of lipomas (anatomical distribution, degree of
symmetry), (4) clinical phenotypes of patients (MERRF, chronic
external ophthalmoplegia—cPEO etc.), (5) correlation between
MSL and other biochemical markers.
This was a retrospective study. The clinical features were
extrapolated from the web-based database in which every item,
considered relevant for mitochondrial disorders in a previous
consensus phase among all involved centers, was evaluated
according to the presence or not (“yes or no”).
MSL severity has been graded considering the number
of anatomical region involved and the symmetry. Data were
expressed as mean± Standard deviation (SD).
The local ethical committees of all involved centers
have approved the database establishment and its use for
scientific purpose.
All enrolled patients, in accordance with the ethical
standards of the 1964 Declaration of Helsinki, have provided
informed consent.
Linear correlation was calculated using Graph pad Prism
6 software, statistical comparisons were tested using Pearson
r test (for correlations) and Student t-test (for means) with
alpha < 0.05.
RESULTS
MSL Incidence in the Database and
Demographic Characteristics
Among the 1,300 patients of the Italian registry, a total of 22
patients from 19 independent families with MSL have been
identified, representing the 1.7% of all subjects of the database.
Fourteen MSL patients were female (63%) and 8 males (37%).
Age of onset was after the second decade in most of the patients
with MSL apart from two sisters with encephalomyopathy with a
very early onset in the first year of life. No differences have been
observed between mean age at onset in male vs. female subjects
(Female 34.5 years vs. Male 35.7 years).
Clinical Characteristics of MSL Patients
The majority of subjects with MSL showed a variety of signs
and symptoms but only in four subjects (18%) it was an isolated
manifestation in a mean follow-up period of about 15 years.
About these four, two were relatives of affected individuals
with other clinical manifestations whereas two were primarily
investigated for a mitochondrial disorder because of lipomas.
Twelve subjects (54.4%) had a diagnosis of MERRF syndrome;
six patients (27%) had a clear myopathy with muscle wasting and
weakness (Table 1).
In two subjects MSL was associated with CPEO. Two
patients had cerebellar ataxia whereas peripheral neuropathy was
observed in five individuals.
Chronic high alcohol intake, diabetes, or dyslipidemia were
not present in any of the individuals with MSL.
Plasma lactate dosage was available in 12 subjects: it was
elevated in all of them of whom 11 had high lactate level at rest
(ranging from 2.7 mEq/l to 4.8 mEq /l, reference values: 0.5–1.5
mEq/l) while only in one subject it was elevated after exercise.
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FIGURE 1 | Schematic representation of lipomas distribution in the study population. In the boxes the frequency of observations in the cohort.
Muscle Morphological and Biochemical
Features
Muscle biopsy was performed in 18 subjects out of 22. RRF and
COX negative fibers were reported in 15 out of 18 (83.2%), two
patients had only RRF, and one (with cPEO) had only type II fiber
atrophy and increased sub-sarcolemma rims at SDH staining.
Dystrophic features were reported in two (one with myopathy,
and the other with cerebellar ataxia and deafness). Biochemical
activities of the respiratory chain enzymes were assessed in 8
individuals; in 3 of them, a reduction of COX activity was
reported, complex II+III were reduced in other 3 subjects, one
individual had a reduction in complex I activity and another one
multiple enzymes defects.
Genetic Description of MSL Cohort
Genetic data showed that most of the patients with MSL (19
patients, 86%) harbored point mutations in mitochondrial DNA
(mtDNA) gene coding for lysine tRNA (tRNALys). Among them,
17 (77% of the MSL cohort) had the m.8344A > G and two
(9%) carried the m.8363G>A. Data on heteroplasmy levels
(expressed as percentage of mutated over wild type mtDNA)
were recorded in blood in 8 patients, in muscle in 7 and in
urine sediment in 6. Mean mutation load was lower in blood
(62.2 ± 17.2), and slightly higher in muscle (88 ± 6%) and
urine sediment (69± 26%).
Multiple deletions of mtDNA were recorded in three
unrelated patients. The genes associated with mtDNA
maintenance (ANT1, POLG1, dGK, and Twinkle) as well
as MFN2 have been sequenced but no causative mutations
were detected.
Lipomas Distribution
Lipomas were distributed symmetrically in 15 patients (68%)
(Figure 1); five subjects had lipomas in a single site (3 in the
neck, 1 in right arm and 1 in gluteus maximum) whereas multiple
involvement was observed in 77% of the cohort with the neck
region as the most affected area (82%) followed by proximal
upper limb and the posterior part of the shoulders (41 and 27%,
respectively). Lipomas were reported in the back in 45% subjects;
abdominal wall was affected in 23% whereas mediastinum was
involved in two individuals.
DISCUSSION
MSLwas firstly described in the late Nineteenth century and since
then, many studies investigated the clinical features and long-
term follow-up of MSL patients (4). Alteration in mitochondrial
function and MSL have been correlated in several reports of
single patients (4). However, no systematic studies have been
conducted to assess MSL prevalence and the associated clinical
features in large cohorts of mitochondrial patients.
In this study we investigate the prevalence and the
characteristics of MSL in the Italian cohort of mitochondrial
patients. Among the subjects enrolled in the registry, lipomas
were reported in 22 (1.7%), confirming that MSL is a
rare disorder even in this specific population. In contrast
with literature data obtained in patients with MSL (4) we
observed a higher presence of MSL in females than males.
Mean age of symptoms onset was overlapping with the one
reported in MERRF syndrome (17, 18). Among the all cohort
of subjects with the m.8344A > G variant in the Italian
registry, the presence of lipomas was reported in 30%. Patients
with MERRF + MSL resulted more severely affected than
MERRF patients.
MSL can be the only clinical manifestation of a mitochondrial
disorder (18% in this cohort). We observed a high association of
myopathy (alone or with other symptoms), probably as part of a
spectrum of the m.8344A>G severity.
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Lactic acid is increased in patients with defect of oxidative
phosphorylation, and it is used as marker for mitochondrial
diseases, even though it lacks of good specificity and sensitivity
(19). Interestingly, all the 12 tested patients have mild to
moderate lactic acidosis. This evidence is interesting and may
point out to the biochemical properties of MSL overlapping
mitochondrial dysfunction (20) and metabolic abnormalities
typically of tumorous tissues.
Regarding anatomical distribution, although lipomas were
symmetric in the majority of the subjects, in one third of the
subjects was not so. This observation, differs from the literature
data (4), and suggests that asymmetry does not rule out the
diagnosis of lipomatosis in mitochondrial diseases. The pattern
of MSL development is similar to the reported distribution for
MSL with lipomas along the midline with neck and shoulders
very frequently involved.
In conclusion, for the first time, this study focuses on a
rare and poorly investigated manifestation of mitochondrial
disease. In patients with mitochondrial diseases, MSL can be
easily overlooked because other clinical picture usually dominate
the clinical course. Our data have demonstrated that MSL is
a rare sign of mitochondrial disease. Identification of MSL
is however important because it could be considered, a red
flag for mitochondrial disorders thus guiding the diagnosis.
Moreover, our data warns to consider to pursue mitochondrial
DNA analysis even in patients with isolated MSL since it
can represent the only manifestation of a pathogenic mtDNA
mutations. Comparing our results with published data from
the literature, we identified some differences that can help
to recognize patient with MSL who deserve mitochondrial
disease investigation: mitochondrial MSL (1) is more frequent in
women, with no history of alcohol abuse, (2) is often associated
with muscle involvement and (3) can be asymmetric. The
association of MSL and elevated lactate level strongly suggests a
mitochondrial disorder.
Our cohort study presents the typical limitations of all
retrospective studies, and probably underestimates the real
prevalence of MSL in patients with mitochondrial diseases,
being a sign that sometimes could be missed when not actively
searched, especially if visceral. However, similar multicenter
efforts are needed and strongly encouraged for rare disorders
such as mitochondrial diseases, and may represent the basis for
more rigorous longitudinal studies.
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